Background: Meyerson's phenomenon is characterized by a symmetrical halo of erythema and scale around central, mostly melanocytic lesions. Objective: Our aim was to describe the dermoscopic and reflectance confocal microscopy (RCM) features of melanocytic tumors less frequently associated with Meyerson's phenomenon, with histopathology and immunohistochemistry correlation. Methods: Clinical, dermoscopic and RCM images of 4 histopathologically confirmed melanocytic tumors associated with Meyerson's phenomenon (3 dysplastic compound nevi and 1 melanoma) were retrospectively collected, with additional immunohistochemical analysis. Results: RCM showed in vivo features of both melanocytic and spongiotic nature of the lesion associated with Meyerson's phenomenon, even in cases with absent halo. Our study also supported the involvement of immune-mediated CD4+ T lymphocyte mechanisms and Langerhans cells. Conclusion: Our case series supports the potential of RCM in the evaluation of tumoral and inflammatory skin diseases. RCM features of rare Meyerson's melanoma were also described for the first time.

1.
Meyerson LB: A peculiar papulosquamous eruption involving pigmented nevi. Arch Dermatol 1971;103:510-512.
2.
Cook-Norris RH, A Zic J, Boyd AS: Meyerson's naevus: a clinical and histopathologic study of 11 cases. Australas J Dermatol 2008;49:191-195.
3.
Pizem J, Stojanovic L, Luzar B: Melanocytic lesions with eczematous reaction (Meyerson's phenomenon) - a histopathologic analysis of 64 cases. J Cutan Pathol 2012;39:901-910.
4.
Rodins K, Byrom L, Muir J: Early melanoma with halo eczema (Meyerson's phenomenon). Australas J Dermatol 2011;52:70-73.
5.
Kus S, Ince U, Candan I, Gurunluonglu R: Meyerson phenomenon associated with dysplastic compound nevi. J Eur Acad Dermatol Venereol 2006;20:350-351.
6.
Vega J, Angel Rodríguez M, Martínez M: Eczematous halo reaction in congenital pigmented nevus. Int J Dermatol 2003;42:895.
7.
Rolland S, Kokta V, Marcoux D: Meyerson phenomenon in children: observation in five cases of congenital melanocytic nevi. Pediatr Dermatol 2009;26:292-297.
8.
Brenan J, Kossard S, Krivanek J: Halo eczema around melanocytic nevi. Int J Dermatol 1985;24:226-229.
9.
Elenitsas R, Halpern AC: Eczematous halo reaction in atypical nevi. J Am Acad Dermatol 1996;34:357-361.
10.
Gabbi TVB, Criado PR, Martins JEC, Omar, ED, Valente NYS: Clinical, dermoscopic and histopathological evaluation of the Meyerson nevus - case report. An Bras Dermatol 2010;85:681-683.
11.
Nicholls DS, Mason GH: Halo dermatitis around a melanocytic naevus: Meyerson's naevus. Br J Dermatol 1988;118:125-129.
12.
Larre Borges A, Zalaudek I, Longo C, Dufrechou L, Argenziano G, Lallas A, Piana S, Moscarella E: Melanocytic nevi with special features: clinical-dermoscopic and reflectance confocal microscopic-findings. J Eur Acad Dermatol Venereol 2014;28:833-845.
13.
Gallais V, Lacour PH, Perrin C, Halioua B, Ortonne JP: Halo eczématiforme autour d'un histiocytofibrome: phénomène de Meyerson. Ann Dermatol Venereol 1993;120:617-620.
14.
Heilig S, Koslosky K, Ioffreda DM, Shin TH, Zaenglein MD: Eczematous nevus sebaceous: a report of three cases. Pediatr Dermatol 2011;28:176-179.
15.
Petit A, Viney C, Gaulier A, Sigal M: Coexistence of Meyerson's with Sutton's naevus after sunburn. Dermatology 1994;189:269-270.
16.
Brandt O, Christophers E, Folster-Holst R: Halo dermatitis followed by the development of vitiligo associated with Sutton's nevi. J Am Acad Dermatol 2005;52(suppl 1):S101-S104.
17.
Petit A, Viney C, Gaulier A, Sigal M: Coexistence of Meyerson's with Sutton's naevus after sunburn. Dermatology 1994;189:269-270.
18.
Zonta E, Chiarion V, Zarian H, Peserico A, Alaibac M: Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α. Melanoma Res 2012;2:284-285.
19.
Hofer T: Meyerson's nevus as primary patch of Gibert pityriasis rosea. A case report. Hautarzt 2002;53:338-341.
20.
Speeckaert R, van Geel N, Vermaelen KV, et al: Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011;24:334-344.
21.
Cox NH, Bloxham CA, Lawrence CM: Halo eczema - resolution after excision of the central naevus alone. Clin Exp Dermatol 1991;16:66-67.
22.
Argenziano G, Soyer HP, Chimentini S, et al: Dermoscopy of pigmented skin lesions: results of a consensus meeting via the internet. J Am Acad Dermatol 2003;48:679-683.
23.
Pellacani G, Cesinaro AM, Seidenari S: Reflectance-mode confocal microscopy of pigmented skin lesions - improvement in melanoma diagnostic specificity. J Am Acad Dermatol 2005;53:979-985.
24.
Longo C, Segura S, Cesinaro AM, Bassoli S, Seidenari S, Pellacani G: An atypical Meyerson's naevus: a dermoscopic, confocal microscopic and immunohistochemical description of one case. J Eur Acad Dermatol Venereol 2007;21:414-416.
25.
Cerroni L, Smolle J, Soyer HP, et al: Immunophenotyping of cutaneous lymphoid infiltrates in frozen and paraffin-embedded tissue sections: a comparative study. J Am Acad Dermatol 1990;22:405-413.
26.
Giacomel J, Zalaudek I, Ferrara G, Argenziano G: Dermoscopy patterns of eczemalike melanoma. Arch Dermatol 2007;143:1081-1082.
27.
Zalaudek I, Manzo M, Ferrara G, Argenziano G: New classification of melanocytic nevi based on dermoscopy. Expert Rev Dermatol 2008;3:477-489.
28.
Astner S, Gonzalez E, Cheung A, et al: Pilot study on the sensitivity and specificity of in vivo reflectance confocal microscopy in the diagnosis of allergic contact dermatitis. J Am Acad Dermatol 2005;53:986-992.
29.
Ardigo M, Longo C, Cristaudo A, Berardesca E, Pellacani G: Evaluation of allergic vesicular reaction to patch test using in vivo confocal microscopy. Skin Res Technol 2012;18:61-63.
30.
Pellacani G, Cesinaro AM, Seidenari S: In vivo assessment of melanocytic nests in nevi and melanomas by reflectance confocal microscopy. Mod Pathol 2005;18:469-474.
31.
Hashemi P, Pulitzer MP, Scope A, Kovalyshyn I, Halpern AC, Marghoob AA: Langerhans cells and melanocytes share similar morphologic features under in vivo reflectance confocal microscopy: a challenge for melanoma diagnosis. J Am Acad Dermatol 2012;66:452-462.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.